Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Huadong Medicine Co Ltd A / Equity Bottom-Up

<ul>
  <li>Huadong is successfully transitioning its business model by focusing on the high-growth, high-margin medical aesthetics sector to offset pricing pressures in its traditional pharmaceuticals business from government policies like Volume-Based Procurement (VBP).</li>
  <li>The company possesses a robust and differentiated product portfolio in both pharmaceuticals and medical aesthetics, with a strong pipeline of innovative drugs and next-generation aesthetic products expected to drive future growth.</li>
  <li>A well-established and extensive distribution and commercialization network across China, particularly in Zhejiang province, provides a significant competitive advantage for launching new products and maintaining market share for existing ones.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Huadong is successfully transitioning its business model by focusing on the high-growth, high-margin medical aesthetics sector to offset pricing pressures in its traditional pharmaceuticals business from government policies like Volume-Based Procurement (VBP).
  The company possesses a robust and differentiated product portfolio in both pharmaceuticals and medical aesthetics, with a strong pipeline of innovative drugs and next-generation aesthetic products expected to drive future growth.
  A well-established and extensive distribution and commercialization network across China, particularly in Zhejiang province, provides a significant competitive advantage for launching new products and maintaining market share for existing ones.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Huadong Medicine Co Ltd A (000963 CH) - Aug 2026

Healthcare Equity Analyst - Emerging & Dev Markets, daaimon

Avien Pillay

Healthcare Equity Analyst - Emerging & Dev Markets

daaimon

daaimon is an independent research company focusing on healthcare and consumer sectors across developed and emerging markets. We produce insightful research which challenges conventional thinking. In particular, we look for new ideas by testing consensus forecasts and markets expectations.

Thematic (Sector/Industry)

<ul>
<li>The obesity problem has escalated at an alarming rate in Asia. </li>
<li>Expect strong growth for GLP-1s over the next few years, however, companies that produce next-generation drugs will take the lead.</li>
<li>The significant increase in newly approved drugs will result in margin pressure - pricing will be key.</li>
</ul>


The obesity problem has escalated at an alarming rate in Asia. 
Expect strong growth for GLP-1s over the next few years, however, companies that produce next-generation drugs will take the lead.
The significant increase in newly approved drugs will result in margin pressure - pricing will be key.


HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Beijing QL Biopharmaceutical / Equity Capital Markets

<ul>
<li>QL adopts a comprehensive business model of "independent R&amp;D + full industrial chain layout + diversified pipeline".Based on proprietary technology platforms, QL is able to form a structural cost advantage.</li>
<li>The competition for GLP-1 is moving from the broad stage to the "efficacy, safety, convenience, and economy" refined competition stage, and QL is facing intense competition in multiple dimensions.</li>
<li>With the comprehensive assessment of QL - "no commercialized product + strong pipeline”, and “first mover advantage + product differentiation", a neutral scenario is HK$15-20 billion market value.</li>
</ul>


QL adopts a comprehensive business model of "independent R&amp;D + full industrial chain layout + diversified pipeline".Based on proprietary technology platforms, QL is able to form a structural cost advantage.
The competition for GLP-1 is moving from the broad stage to the "efficacy, safety, convenience, and economy" refined competition stage, and QL is facing intense competition in multiple dimensions.
With the comprehensive assessment of QL - "no commercialized product + strong pipeline”, and “first mover advantage + product differentiation", a neutral scenario is HK$15-20 billion market value.


Pre-IPO Beijing QL Biopharmaceutical - Valuation Premiums Are Highly Likely

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass), with Int’l Compass reports all echoing this sentiment.</li>
<li>We will maintain our bullish intermediate-term view as long as market dynamics remain healthy and the SPX and ACWI-US are above 6028-6059 (up from 5700-5785) and $119-$121.</li>
<li>$128, $125-$126, and $123-$123.50 are short-term supports to watch on ACWI-US; we will maintain our near-term bullish outlook as long as $123 support holds.</li>
</ul>


We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass), with Int’l Compass reports all echoing this sentiment.
We will maintain our bullish intermediate-term view as long as market dynamics remain healthy and the SPX and ACWI-US are above 6028-6059 (up from 5700-5785) and $119-$121.
$128, $125-$126, and $123-$123.50 are short-term supports to watch on ACWI-US; we will maintain our near-term bullish outlook as long as $123 support holds.


Continue Adding Exposure to China; Short-Term Supports to for This ACWI-US Pullback

<ul>
<li>We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass).</li>
<li>We will maintain our bullish view as long as market dynamics remain healthy and the SPX and ACWI-US are above 5700-5785 and $120-$121 (up from 5500 and $115).</li>
<li>We are upgrading Korea(KOSPI) to overweight; we discussed May 30 several Financials and other stocks to buy. KOSPI has exploded higher since, and is now reversing its 2-year RS downtrend.</li>
</ul>


We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass).
We will maintain our bullish view as long as market dynamics remain healthy and the SPX and ACWI-US are above 5700-5785 and $120-$121 (up from 5500 and $115).
We are upgrading Korea(KOSPI) to overweight; we discussed May 30 several Financials and other stocks to buy. KOSPI has exploded higher since, and is now reversing its 2-year RS downtrend.


Upgrading Korea to Overweight; MSCI ACWI and Emerging Market Breakouts

China

Huadong Medicine Co., Ltd. wholesales and retails medicines, pharmaceutical preparations, biological products, and medical instruments.  Through its subsidiaries, the Company also manufactures antibiotic medicines and biochemical products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Huadong Medicine Co Ltd A (000963 CH)

Primer: Huadong Medicine Co Ltd A (000963 CH) - Aug 2026

Huadong is successfully transitioning its business model by focusing on the high-growth, high-margin medical aesthetics sector to offset pricing...

αSK Primers

The GLP-1 Landscape in Asia

First-gen GLP-1 impact may fall short of hype, demand still strong. Next-gen drugs promise better results, tolerance, price. Expect margin pressure...

daaimon

Pre-IPO Beijing QL Biopharmaceutical - Valuation Premiums Are Highly Likely

QL's technology platforms give it a cost advantage, but faces intense competition.Neutral market value estimated at HK$15-20bn.Top institutions...

Xinyao (Criss) Wang

Continue Adding Exposure to China; Short-Term Supports to for This ACWI-US Pullback

Continue Adding Exposure to China; $ACWI Short-Term Supports for this pullback: $128, $125-$126, and $123-$123.50. Pullbacks = buy opportunities,...

Vermilion Research

Upgrading Korea to Overweight; MSCI ACWI and Emerging Market Breakouts

MSCI $ACWI and Emerging Market $EEM Breakouts; Upgrading Korea $EWY to Overweight; Downgrading Broad Europe, but staying Overweight Germany,...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: Huadong Medicine Co Ltd A (000963 CH) - Aug 2026

Huadong is successfully transitioning its business model by focusing on the high-growth, high-margin medical aesthetics sector to offset pricing...

αSK Primers

The GLP-1 Landscape in Asia

First-gen GLP-1 impact may fall short of hype, demand still strong. Next-gen drugs promise better results, tolerance, price. Expect margin pressure...

daaimon

Pre-IPO Beijing QL Biopharmaceutical - Valuation Premiums Are Highly Likely

​QL's technology platforms give it a cost advantage, but faces intense competition.Neutral market value estimated at HK$15-20bn.Top institutions...

Xinyao (Criss) Wang

Continue Adding Exposure to China; Short-Term Supports to for This ACWI-US Pullback

Continue Adding Exposure to China; $ACWI Short-Term Supports for this pullback: $128, $125-$126, and $123-$123.50. Pullbacks = buy opportunities,...

Vermilion Research

Upgrading Korea to Overweight; MSCI ACWI and Emerging Market Breakouts

MSCI $ACWI and Emerging Market $EEM Breakouts; Upgrading Korea $EWY to Overweight; Downgrading Broad Europe, but staying Overweight Germany,...

Vermilion Research

QL's technology platforms give it a cost advantage, but faces intense competition.Neutral market value estimated at HK$15-20bn.Top institutions...